Inclusion of Elderly Patients Urged in EMA Cancer Drug Development Guidance

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency (EMA) has finalized a revised guideline on anticancer drug development, placing special emphasis on the inclusion of elderly patients in clinical trials.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00